Zeneca/Voluntary Hospitals of America
Executive Summary
Sign five-year deal for VHA to market to its hospitals the general anesthetic for ICU use Dipriven (propofol) and the cephalosporin Cefoten (cefotetan) under its private label VHA+PLUS. Zeneca says the deal will enhance usage of Cefotan as the only second-generation cephalosporin VHA+PLUS drug and will keep sales levels up for Diprivan until 1999. Diprivan's patent expires in 1996. VHA has 1,103 hospitals in its network, representing "nearly 18% of all community hospitals in the country"